Progress in Neurotherapeutics and Neuropsychopharmacology

Review Article

Progress in Neurotherapeutics and Neuropsychopharmacology 2007

Jeffrey L. Cummings a1c1
a1 Deane F. Johnson Center for Neurotherapeutics at UCLA; UCLA Alzheimer Disease Center, Augustus Rose Professor of Neurology, Professor of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Email:

Article author query
cummings jl   [PubMed][Google Scholar] 


There continues to be progress in neurotherapeutics and neuropsychopharmacology with each advancing year. Production of new molecular entities (NME's) remains small, but advances are being made in repurposing agents and extending their indications, obtaining more safety and tolerability data in long term and extension studies, introducing novel trial methodologies that provide insight into how to best to conduct trials and how best to treat diseases, and developing new formulations that improve adherence and decrease the barriers to patient compliance. Advances in how to test potential disease-modifying agents in patients with progressive neurological illnesses is advancing. Promising biomarkers have been identified in some neurological diseases.

Key Words: Clinical trials; drug development; futility trials; Parkinson's disease; Amyotrophic Lateral Sclerosis; Schizophrenia.

c1 Correspondence should be addressed to: Jeffrey L. Cummings, MD, Alzheimer Disease Center, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095 7226, USA; Ph: +1 310 794 3665; Fax: +1 310 794 3148;